$5.75
▼ -1.4% Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Atea (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Atea Pharmaceuticals Q2 Earnings Call Highlights
Overview
52-week range
$2.78
$6.45
81% of range
Avg surprise (last 3)
+12.6%
Avg reaction (last 2)
+5.2%
100% positive
Latest IV / EM
192%
EM ±30.0% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.41 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.57 | $-0.60 | +5.0% | -42.5% | +1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.53 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.44 | $-0.46 | +4.3% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.40 | $-0.56 | +28.6% | — | +8.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.37 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.48 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.75 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.40 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.43 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-35M | $-48M | — | $-46M | $-41M | $-39M | — | $-37M |
| Net income | $-33M | $-45M | — | $-42M | $-37M | $-34M | — | $-31M |
| EPS (diluted) | $-0.41 | $-0.57 | — | $-0.53 | $-0.44 | $-0.40 | — | $-0.37 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $77M | $79M | $96M | $77M | $88M | $119M | $65M | $98M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $229M | $263M | $311M | $336M | $386M | $434M | $462M | $487M |
| Total assets | $232M | $267M | $315M | $343M | $392M | $440M | $465M | $491M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | $27M | $27M | $29M | $26M | $32M |
| Total equity | $204M | $234M | $275M | $316M | $364M | $411M | $439M | $459M |